Private equity firm AH Bio Fund II established its first $5 million position in SCTX, increasing its stake by 16.2% at $15.00 near the stock's 90-day low. This move expands the existing insider buying cluster to 5 members with $35.1M in total recent purchases.

Where it could go — Our 7-8 conviction institutional buys: 67% beat SPY at 30d with +6.7% average outperformance; watch for continued cluster expansion.

OrbiMed Advisors, a director, bought $15M worth of SCTX at $15.00 per share, increasing its stake by 286.7% and entering near the 90-day low. This marks OrbiMed's first-ever purchase on SCTX and significantly strengthens an existing cluster that includes CEO Carl Gordon's $15M buy and two officer purchases totaling $85K, all executed near price lows. Bull: sustained cluster growth and insider conviction at depressed levels → target $20+; bear: breaks $14.50 support.

Where it could go — Our 7-8 conviction buys: 67% beat SPY at 30d; bull holds $15, bear breaks $14.50.

Director Aghazadeh Behzad bought $36.3M of SCTX at $15.16, increasing his stake by 342.8% and entering at a price just 12.4% above the 90-day low. This first-ever purchase by a long-tenured director at a significant discount to recent highs, alongside two officers buying $85K, suggests strong belief in undervaluation. Bull: holds above $17.31 → targets $20+; bear breaks $15.16.

Where it could go — Our 7-8 conviction director buys: 67% beat SPY at 30d; bull holds $17.31, bear breaks $15.16.